Completed PHASE3 INTERVENTIONAL 2-arm NCT00971152

Effect of a Higher Than Maximum 450IU Gonadotropin Dose in an In-vitro Fertilization Cycle

Effect of a Higher Than Maximum 450IU Gonadotropin Dose on Patient Outcomes in an In-Vitro Fertilization Setting: a Randomized Controlled Non-infertility Trial

Sponsor: Clinique Ovo

Conditions Subfertility

Interventions menotropins for injection urofollitropin for injection

Updated 6 times since 2017 Last updated: Mar 12, 2014 Started: Sep 30, 2009 Primary completion: Oct 31, 2013 Completion: Feb 28, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Subfertility, this trial is completed. The trial is conducted by Clinique Ovo and has accumulated 6 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Oct 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Oct 2021 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Sep 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Clinique Ovo
Ferring Pharmaceuticals

Data source: Clinique Ovo

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Montreal, Canada